Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 1, 2020

QIAGEN receives FDA’s EUA for coronavirus detection kit

QIAGEN has received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its QIAstat-Dx Respiratory SARS-CoV-2 Panel test to diagnose patients infected with coronavirus (Covid-19).

The newly developed test kit is the first and only syndromic solution integrating detection of SARS-CoV-2 coronavirus.

QIAstat-Dx test kit can differentiate SARS-CoV-2 from 20 other serious respiratory infections in patients and is capable of delivering results in about one hour.

Related Companies

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU